Mr. Ken d'Entremont reports

MEDEXUS SCHEDULES SECOND FISCAL QUARTER 2025 CONFERENCE CALL

Medexus Pharmaceuticals Inc. plans to host a conference call at 8 a.m. Eastern Time on Friday, Nov. 8, 2024, to discuss Medexus's results for its second fiscal quarter ended Sept. 30, 2024. Medexus expects to file its financial statements and MD&A (management's discussion and analysis) after markets close on Nov. 7, 2024.

To participate in the call, please dial the following numbers:

• 888-506-0062 (toll-free) for Canadian and United States callers;
• 1-973-528-0011 for international callers;
• Access code: 511254.

A live webcast of the call will be available on the investors section of Medexus's corporate website.

A replay of the call will be available approximately one hour following the end of the call through Friday, Nov. 15, 2024. To access the replay, please dial the following numbers 1-877-481-4010 for Canadian and U.S. callers 1 919-882-2331 for international callers.

Conference ID:  51522

A replay of the webcast will be available on the Investors section of Medexus's corporate website until Saturday, Nov. 8, 2025.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology.

We seek Safe Harbor.